CASE STUDY World-first clinical trial improves patient outcomes for kidney transplants
Dr Michael Collins
Royal Adelaide Hospital
Filmed August 2023
A world-first clinical trial conducted at the Royal Adelaide Hospital (RAH) and at hospitals across Australia and New Zealand has identified the best fluid treatment to reduce the risk of patients requiring dialysis after a kidney transplant.
Around one in three people who receive a kidney transplant suffer delayed graft function, which means the transplant doesn’t work immediately and they require dialysis.
The lead-author of the study, was Royal Adelaide Hospital Nephrologist and University of Adelaide researcher, Dr Michael Collins.
During the four-year study, fluids were trialled in 808 patients with kidney failure, who received a kidney transplant from a deceased organ donor at the RAH and 15 other hospitals in Australia and New Zealand.
Researchers at the University of Adelaide and University of Sydney, found 30 per cent of participants who received Plasma-Lyte 148 needed dialysis after transplant, compared with 40 per cent of participants who received saline.
The results of the study are now being used to improve the health of kidney transplant patients in Australia and New Zealand and it is likely that practice will change at transplant units around the world.
-
Environmental exposure to function of lung epithelial stem cell biology
Dr Clare Weeden has recently commenced as a Laboratory Head at WEHI in 2025, supported by the CSL Centenary Fellowship.
Dr Weeden specialises in lung epithelial cell biology in the context of homeostasis, inflammation, and lung cancer, particularly in people who don’t smoke. Her work endeavours to understand how past environmental exposures shape the responses of lung cells and the molecular mechanisms underlying this cellular recall, with the aim to develop novel early detection strategies for lung disease.
-
Oral administration of insulin for Type 1 Diabetes
Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.
People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.
Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.
-
Muscle Cell Communication and Repair
Dr. William Roman is a Group Leader at the Australian Regenerative Medicine Institute (ARMI) at Monash University. He obtained his PhD from Paris Descartes University and Freie University of Berlin, focusing on nuclear positioning during skeletal muscle development. Dr. Roman’s research journey has taken him across the globe, including postdoctoral work in Barcelona, tissue engineering in Lisbon, and a brief stint at Stanford University.
At ARMI, Dr. Roman leads innovative research on intercellular communication within muscle organs. His work involves growing human muscles on chips to understand how skeletal muscle cells interact with neurons and tendons. This research aims to develop better models for studying muscle diseases, drug screening, and even applications in cellular agriculture and biorobotics.
